Clinical Trial Update: Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Afatinib in combination with weekly Paclitaxel as second-line therapy for HER-2 positive gastric and gastroesophageal/esophageal canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Cancer

Drugs mentioned

• Afatinib (afatinib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Columbia University | Conditions: HER-2 Positive Gastric Cancer, Gastrooesophageal Cancer | Phase 2 | Status: WITHDRAWN